Kuros (Kuros Biosciences) Aktie

27,40 EUR +0,55 EUR +2,05 %

09:23:17

STU

26,24 CHF +0,62 CHF +2,42 %

10:45:31

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.1,05 Mrd. EUR

Div. Rendite0,00%

WKNA2ALS5

ISINCH0325814116

SymbolCSBTF

Kuros (Kuros Biosciences) Aktien News

Sortieren:Datum Meistgelesen

13.05.25GlobeNewswireKuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich

15.04.25GlobeNewswireAnnual General Meeting of Kuros Biosciences approves all resolutions

15.04.25GlobeNewswireKuros Biosciences reports 82% year over year increase in sales in the first three months of 2025

WerbungKuros (Kuros Biosciences)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

11.03.25GlobeNewswireKuros Biosciences grows sales to CHF 75.6 million for 2024

07.01.25EQS GroupKuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division

19.11.24EQS GroupKuros Biosciences Expands into Extremities Markets

10.10.24EQS GroupKuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024

08.08.24EQS GroupKuros Biosciences Reports First Half of 2024 Results

25.06.24EQS GroupKuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

24.04.24EQS GroupKuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales

17.04.24EQS GroupAnnual General Meeting of Kuros Biosciences approves all resolutions

13.03.24EQS GroupKuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

08.03.24EQS GroupKuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

01.02.24EQS GroupKuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

31.01.24EQS GroupKuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

04.01.24EQS GroupKuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

27.12.23EQS GroupKuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

28.11.23EQS GroupKuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

12.10.23EQS GroupKuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management

09.08.23EQS GroupKuros Biosciences Reports Results for First Half 2023

13.07.23EQS GroupKuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

08.05.23EQS GroupAnnual General Meeting of Kuros Biosciences approves all resolutions

27.04.23EQS GroupKuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023

15.03.23EQS GroupKuros Biosciences reports results for the full year 2022

21.02.23EQS GroupKuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft

16.02.23EQS GroupKuros Biosciences Announces Changes to Executive Management Team

23.11.22EQS GroupKuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

02.11.22EQS GroupKuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules

26.10.22EQS GroupKuros reports 73% increase in MagnetOs sales in first nine months of 2022

19.10.22EQS GroupKuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week

11.10.22EQS GroupKuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

03.10.22EQS GroupKuros Biosciences Appoints Chris Fair as Chief Operating Officer

15.09.22EQS GroupKuros Biosciences announces successful CHF 6.0 million private placement

23.08.22EQS GroupKuros Biosciences MagnetOs Bone Graft Successfully Achieves Three Key Milestones

09.08.22EQS GroupKuros Biosciences reports results for the first six months of 2022

08.06.22EQS GroupAnnual General Meeting of Kuros Biosciences approves all resolutions

02.06.22EQS GroupKuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment

31.05.22EQS GroupKuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial

Kuros (Kuros Biosciences) News

Kuros (Kuros Biosciences) News: auf dieser Seite finden Sie alle Kuros (Kuros Biosciences) News und Nachrichten zur Kuros (Kuros Biosciences) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Kuros (Kuros Biosciences) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Kuros (Kuros Biosciences) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.